|
|
Vaccine Detail
|
Tetanus peptide melanoma vaccine |
| Vaccine Information |
- Vaccine Name: Tetanus peptide melanoma vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: 12 melanoma peptides restricted by Class I MHC (NCT00071981)
- Immunization Route: intradermal and subcutaneous
- Description: This is a vaccine consisting of peptides derived from melanoma-associated antigens and a modified T-cell epitope derived from tetanus toxoid. Vaccination with this agent may stimulate a host cytotoxic and helper T-cell response against tumor cells expressing melanoma-associated antigens, resulting in decreased tumor growth. (NCIT_C2468) This vaccine is compromised of multi-epitope melanoma peptide vaccine (12MP) and 1 tetanus peptide melanoma vaccine emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant). (NCT00071981)
|
| Host Response |
|
|
| References |
NCIT_C2468: Tetanus Peptide Melanoma Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C2468]
NCT00071981: Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma [https://clinicaltrials.gov/study/NCT00071981]
|
|
